Logo image
Se connecter
Retour
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
Article de revue   Open Access   Avec comité de lecture

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Claire Gourzones, Céline Bellanger, Sylvain Lamure, Ouissem Karmous Gadacha, Elvira Garcia de Paco, Laure Vincent, Guillaume Cartron, Bernard Klein et Jérôme Moreaux
Cancers, Vol.11(4)
04/2019
DOI: https://doi.org/10.3390/cancers11040439
PMCID: PMC6521290
PMID: 30925767

Résumé

reactive oxygen species multiple myeloma melphalan drug resistance NRF2 GSH
Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development of drug resistance remains a major problem for effective treatment of MM. Understand the mechanisms underlying drug resistance in MM is a focal point to improve MM treatment.

Fichiers et liens (2)

url
Find in HALAfficher
url
https://doi.org/10.3390/cancers11040439Afficher
Published (Version of record) Ouvrir

Indicateurs

1 Consultations de la notice

Détails

Logo image